Generated by AI
Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.
Website1000 Park Forty Plaza
Durham, NC, 27713
United States
The latest articles about IMVT.
Motley Fool Press Release.
Summary of Sep 23's posts. Generated by AI.
Summary of May 21's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about IMVT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.